Company news

Wave Life Sciences Ltd. news in 2025

Wave Life Sciences Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

December 8, 2025

Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

December 7, 2025

Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss

December 7, 2025

Wave Life Sciences to Announce Interim Data from the Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity on Monday, December 8, 2025

December 6, 2025

Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update

November 9, 2025

Wave Life Sciences to Present at Upcoming Investor Conferences

November 6, 2025

Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025

November 3, 2025

Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025

November 3, 2025

Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

October 28, 2025

Correcting and Replacing Wave Life Sciences Announced Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity During Annual Research Day

October 28, 2025

Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences

September 17, 2025

Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

September 2, 2025

Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

July 29, 2025

Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025

July 22, 2025

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions

June 19, 2025

Wave Life Sciences to Present at 2025 Jefferies Global Healthcare Conference

May 28, 2025

Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

May 27, 2025

Wave Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025

Wave Life Sciences First Quarter 2025 Financial Results Scheduled for May 8, 2025

April 30, 2025

Wave Life Sciences Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE-N531

March 25, 2025

Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 3, 2025

Wave Life Sciences Fourth Quarter and Full Year 2024 Financial Results Scheduled for March 4, 2025

February 24, 2025

Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity

February 5, 2025

Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation

January 12, 2025

Calls in 2025

Decks in 2025